-
Oct 9, 2024 | 
brnw.ch | Alexandra Thomas |Erica L. Mayer |Angela DeMichele
COMMENTS AND CONTROVERSIES The use of tissue-based genomic assays as a tool for risk stratification in early-stage estrogen receptor (ER)–positive breast cancer marks a significant advance over the previous paradigm which relied largely on extent of disease to assess risk.1-3 This advance has transformed care, with genomic assays identifying patients who do not benefit from adjuvant chemotherapy.4 However, prospective trials testing the clinical utility of genomic assays largely excluded...
-
Feb 6, 2024 | 
onclive.com | Kevin Kalinsky |Erica L. Mayer
Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 MutationsDrs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.
-
Jan 30, 2024 | 
onclive.com | Erica L. Mayer |Kevin Kalinsky
The Role of Elacestrant in Breast CancerErica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.
-
Jan 30, 2024 | 
onclive.com | Kevin Kalinsky |Erica L. Mayer
Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.
-
Jan 23, 2024 | 
onclive.com | Kevin Kalinsky |Erica L. Mayer
Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon CancerctDNA Is Predictive of DFS, Offers Prognostic Tool in CRCFrontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRCDr Li on the Use of ADG126 With Pembrolizumab in MSS CRC
-
Jan 16, 2024 | 
onclive.com | Kevin Kalinsky |Erica L. Mayer
Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.
-
Jan 16, 2024 | 
onclive.com | Kevin Kalinsky |Erica L. Mayer
This is a synopsis of an Insights series featuring Kevin Kalinsky, MD, MS, of Winship Cancer Institute of Emory University, and Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute.
-
Dec 1, 2023 | 
onclive.com | Erica L. Mayer
Erica L. Mayer, MD, MPH, director, Breast Cancer Clinical Research, Dana-Farber and Brigham and Women’s Hospital, institute physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer. CDK4/6 inhibitors are integral to the management of HR-positive breast cancer, Mayer says.
-
Jun 14, 2023 | 
jamanetwork.com | Olga Kantor |Rachel A. Freedman |Erica L. Mayer |Mariana Chavez- MacGregor
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial
Key PointsQuestion
Are there differences in locoregional recurrence by race and ethnicity among patients with hormone receptor–positive, node-negative, early-stage breast cancer?
-
Jun 2, 2023 | 
nature.com | Priscilla K Brastianos |Anita Giobbie-Hurder |Beth Overmoyer |Sara M. Tolaney |Erica L. Mayer
AbstractBrain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments. Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies.
